Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 18 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-1.64 Insider Own1.02% Shs Outstand70.68M Perf Week-17.98%
Market Cap488.50M Forward P/E- EPS next Y-1.77 Insider Trans0.00% Shs Float70.17M Perf Month-21.17%
Income-88.45M PEG- EPS next Q-0.38 Inst Own62.01% Short Float25.27% Perf Quarter-36.14%
Sales0.43M P/S1136.05 EPS this Y-4.22% Inst Trans10.67% Short Ratio3.55 Perf Half Y160.98%
Book/sh2.75 P/B2.51 EPS next Y-2.43% ROA-42.36% Short Interest17.73M Perf Year20.88%
Cash/sh2.79 P/C2.47 EPS next 5Y- ROE-46.63% 52W Range2.09 - 14.84 Perf YTD-38.76%
Dividend Est.- P/FCF- EPS past 5Y35.74% ROI-45.53% 52W High-53.57% Beta0.20
Dividend TTM- Quick Ratio17.25 Sales past 5Y115.21% Gross Margin- 52W Low229.67% ATR (14)0.76
Dividend Ex-DateJan 20, 2017 Current Ratio17.25 EPS Y/Y TTM7.39% Oper. Margin-19603.29% RSI (14)32.69 Volatility7.48% 8.69%
Employees59 Debt/Eq0.00 Sales Y/Y TTM-91.60% Profit Margin-20762.21% Recom1.29 Target Price22.00
Option/ShortYes / Yes LT Debt/Eq0.00 EPS Q/Q-25.03% Payout- Rel Volume0.64 Prev Close7.04
Sales Surprise1661.90% EPS Surprise-18.68% Sales Q/Q133.64% EarningsMar 27 BMO Avg Volume4.99M Price6.89
SMA20-20.88% SMA50-28.47% SMA20017.32% Trades Volume3,204,038 Change-2.13%
Date Action Analyst Rating Change Price Target Change
Jan-24-24Initiated Goldman Neutral $13
Mar-22-23Downgrade Goldman Buy → Neutral $20 → $6
Dec-01-22Initiated Goldman Buy $20
Dec-29-21Resumed Jefferies Buy $30
Jun-02-21Initiated H.C. Wainwright Buy $35
Feb-11-21Initiated Guggenheim Buy $36
Dec-14-20Initiated Jefferies Buy $25
Nov-12-20Reiterated B. Riley Securities Buy $31 → $28
Sep-25-20Initiated B. Riley FBR Buy $31
Aug-14-20Initiated Evercore ISI Outperform
Mar-29-24 12:00PM
Mar-28-24 10:49AM
Mar-27-24 06:29PM
07:00AM Loading…
Mar-20-24 07:30AM
Feb-26-24 09:26AM
Feb-20-24 10:26AM
Feb-13-24 03:07PM
Jan-02-24 07:30AM
Dec-01-23 11:45AM
Nov-30-23 04:24PM
Nov-08-23 09:15AM
07:00AM Loading…
Nov-07-23 07:00AM
Oct-31-23 07:30AM
Oct-26-23 07:30AM
Oct-25-23 07:30AM
Oct-17-23 07:30AM
Sep-26-23 07:30AM
Sep-12-23 07:30AM
Aug-30-23 07:30AM
Aug-10-23 07:00AM
Aug-03-23 07:30AM
Aug-01-23 07:30AM
Jun-27-23 09:56AM
Jun-16-23 07:30AM
Jun-15-23 07:30AM
May-31-23 07:30AM
07:00AM Loading…
May-11-23 07:00AM
May-08-23 07:30AM
May-04-23 07:30AM
Apr-11-23 07:30AM
Mar-27-23 04:05PM
Mar-21-23 07:00AM
Feb-28-23 07:00AM
Feb-21-23 07:30AM
Jan-04-23 07:30AM
Dec-20-22 07:00AM
Nov-22-22 07:30AM
Nov-10-22 07:00AM
Nov-03-22 07:30AM
Oct-28-22 07:30AM
Sep-28-22 07:30AM
Sep-14-22 07:00AM
Aug-11-22 07:00AM
Aug-04-22 07:30AM
Jul-07-22 08:17AM
Jun-17-22 07:30AM
Jun-08-22 09:55AM
May-31-22 07:30AM
May-23-22 09:55AM
May-20-22 07:30AM
May-16-22 07:30AM
May-14-22 09:51AM
May-12-22 07:00AM
May-05-22 07:30AM
Apr-01-22 03:40PM
Mar-22-22 12:47PM
Mar-15-22 07:01AM
Mar-08-22 07:00AM
Feb-17-22 03:02PM
Jan-31-22 07:00AM
Jan-28-22 04:36AM
Jan-24-22 02:48PM
Jan-03-22 07:00AM
Dec-13-21 06:00AM
Nov-22-21 04:01PM
Nov-10-21 04:01PM
Nov-09-21 04:01PM
Nov-03-21 04:01PM
Nov-01-21 03:01PM
Oct-15-21 09:35PM
Oct-13-21 04:30PM
Oct-11-21 03:51PM
Oct-06-21 04:01PM
Oct-04-21 07:00AM
Oct-03-21 08:53PM
Oct-01-21 05:15PM
Sep-29-21 06:15PM
Sep-28-21 07:01AM
Sep-27-21 04:01PM
Sep-17-21 06:12AM
Sep-07-21 04:01PM
Sep-02-21 06:21AM
Aug-27-21 08:31AM
Aug-10-21 04:01PM
Aug-04-21 04:01PM
Aug-03-21 03:00PM
Jul-04-21 03:39AM
Jun-29-21 04:01PM
Jun-17-21 01:15AM
Jun-16-21 07:00AM
Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Roberts M ScotChief Scientific OfficerFeb 02 '24Option Exercise0.007,775044,990Feb 05 06:02 PM
Harris Matthew ScottChief Medical OfficerFeb 02 '24Option Exercise0.007,775055,965Feb 05 06:01 PM
Garg Vipin KPresident and CEOFeb 02 '24Option Exercise0.0018,9500300,404Feb 05 06:00 PM
Garg Vipin KPresident and CEOFeb 01 '24Option Exercise0.0016,5450288,767Feb 05 06:00 PM
Harris Matthew ScottChief Medical OfficerFeb 01 '24Option Exercise0.006,166049,991Feb 05 06:01 PM
Roberts M ScotChief Scientific OfficerFeb 01 '24Option Exercise0.006,166039,016Feb 05 06:02 PM
Roberts M ScotChief Scientific OfficerJan 30 '24Option Exercise0.009,275029,699Feb 01 06:03 PM
Garg Vipin KPresident and CEOJan 30 '24Option Exercise0.0026,7750276,030Feb 01 06:01 PM
Harris Matthew ScottChief Medical OfficerJan 30 '24Option Exercise0.009,275043,277Feb 01 06:01 PM
Eisenstadt Richard IChief Financial OfficerJan 30 '24Option Exercise0.009,275042,566Feb 01 06:00 PM
Jordt Raymond MChief Business OfficerJan 01 '24Option Exercise0.009,375011,207Jan 04 06:00 PM
Eisenstadt Richard IChief Financial OfficerDec 29 '23Option Exercise0.0012,500036,335Jan 02 06:00 PM
Drutz DavidDirectorAug 15 '23Buy2.8830086229,785Aug 15 06:46 PM